These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38996180)

  • 21. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two novel mutations in the homogentisate-1,2-dioxygenase gene identified in Chinese Han Child with Alkaptonuria.
    Li H; Zhang K; Xu Q; Ma L; Lv X; Sun R
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):453-6. PubMed ID: 25153563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Founder effects of the homogentisate 1,2-dioxygenase (HGD) gene in a gypsy population and mutation spectrum in the gene among alkaptonuria patients from India.
    Danda S; Mohan S; Devaraj P; Dutta AK; Nampoothiri S; Yesodharan D; Phadke SR; Jalan AB; Thangaraj K; Verma IC; Danda D; Jebaraj I
    Clin Rheumatol; 2020 Sep; 39(9):2743-2749. PubMed ID: 32212000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural history of alkaptonuria revisited: analyses based on scoring systems.
    Ranganath LR; Cox TF
    J Inherit Metab Dis; 2011 Dec; 34(6):1141-51. PubMed ID: 21748407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Untargeted NMR Metabolomics Reveals Alternative Biomarkers and Pathways in Alkaptonuria.
    Grasso D; Geminiani M; Galderisi S; Iacomelli G; Peruzzi L; Marzocchi B; Santucci A; Bernini A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.
    Hughes JH; Liu K; Plagge A; Wilson PJM; Sutherland H; Norman BP; Hughes AT; Keenan CM; Milan AM; Sakai T; Ranganath LR; Gallagher JA; Bou-Gharios G
    Hum Mol Genet; 2019 Dec; 28(23):3928-3939. PubMed ID: 31600782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an Effective Therapy for Alkaptonuria - Lessons for Osteoarthritis.
    Gallagher JA; Dillon JP; Ranganath LR
    Rheumatol Immunol Res; 2021 Jun; 2(2):79-85. PubMed ID: 36465977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventive use of nitisinone in alkaptonuria.
    Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ
    Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward a generalized computational workflow for exploiting transient pockets as new targets for small molecule stabilizers: Application to the homogentisate 1,2-dioxygenase mutants at the base of rare disease Alkaptonuria.
    Bernini A; Galderisi S; Spiga O; Bernardini G; Niccolai N; Manetti F; Santucci A
    Comput Biol Chem; 2017 Oct; 70():133-141. PubMed ID: 28869836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
    Kisa PT; Gunduz M; Dorum S; Uzun OU; Cakar NE; Yildirim GK; Erdol S; Hismi BO; Tugsal HY; Ucar U; Gorukmez O; Gulten ZA; Kucukcongar A; Bulbul S; Sari I; Arslan N
    Eur J Med Genet; 2021 May; 64(5):104197. PubMed ID: 33746036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Discovery of the Mode of Action of Nitisinone.
    Lock EA
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in Alkaptonuria Patients and Establishment of a Novel LOVD-Based HGD Mutation Database.
    Zatkova A; Sedlackova T; Radvansky J; Polakova H; Nemethova M; Aquaron R; Dursun I; Usher JL; Kadasi L
    JIMD Rep; 2012; 4():55-65. PubMed ID: 23430897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in Italy.
    Nemethova M; Radvanszky J; Kadasi L; Ascher DB; Pires DE; Blundell TL; Porfirio B; Mannoni A; Santucci A; Milucci L; Sestini S; Biolcati G; Sorge F; Aurizi C; Aquaron R; Alsbou M; Lourenço CM; Ramadevi K; Ranganath LR; Gallagher JA; van Kan C; Hall AK; Olsson B; Sireau N; Ayoob H; Timmis OG; Sang KH; Genovese F; Imrich R; Rovensky J; Srinivasaraghavan R; Bharadwaj SK; Spiegel R; Zatkova A
    Eur J Hum Genet; 2016 Jan; 24(1):66-72. PubMed ID: 25804398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.